126 related articles for article (PubMed ID: 36762609)
1. Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study.
Ogdie A; Shaw Y; Almonte M; Maksabedian Hernandez EJ; Stolshek B; Michaud K
ACR Open Rheumatol; 2023 Apr; 5(4):167-172. PubMed ID: 36762609
[TBL] [Abstract][Full Text] [Related]
2. Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis.
Ogdie A; Maksabedian Hernandez EJ; Shaw Y; Stolshek B; Michaud K
ACR Open Rheumatol; 2022 Nov; 4(11):935-941. PubMed ID: 35971643
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
4. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
6. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
7. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
8. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
10. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
11. Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis.
Behrens F; Koehm M; Schwaneck EC; Schmalzing M; Wittig BM; Gnann H; Greger G; Tony HP; Burkhardt H
Scand J Rheumatol; 2019 Sep; 48(5):375-382. PubMed ID: 31311386
[No Abstract] [Full Text] [Related]
12. Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis.
Mantravadi S; George M; Brensinger C; Du M; Baker JF; Ogdie A
BMC Rheumatol; 2020; 4():39. PubMed ID: 32905192
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
14. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
Christensen IE; Lillegraven S; Mielnik P; Bakland G; Loli L; Sexton J; Uhlig T; Kvien TK; Provan SA
Ann Rheum Dis; 2022 Mar; 81(3):398-401. PubMed ID: 34625404
[TBL] [Abstract][Full Text] [Related]
15. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
[TBL] [Abstract][Full Text] [Related]
16. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
17. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
[TBL] [Abstract][Full Text] [Related]
18. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
Helliwell PS; Taylor WJ;
J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
[TBL] [Abstract][Full Text] [Related]
20. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort.
Nikiphorou E; Negoescu A; Fitzpatrick JD; Goudie CT; Badcock A; Östör AJ; Malaviya AP
Clin Rheumatol; 2014 May; 33(5):609-14. PubMed ID: 24609758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]